Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging

Mattia Boeri, Stefano Sestini, Orazio Fortunato, Carla Verri, Paola Suatoni, Ugo Pastorino, Gabriella Sozzi

Research output: Contribution to journalArticle

Abstract

Lung cancer is the leading cause of cancer deaths in the world. Advances in early detection crucial to enable timely curative surgery have been made in recent years. Cost-benefit profiles of lung cancer screening in smokers by low-dose computed tomography are still under evaluation. In particular, the high false-positive rates of low-dose computed tomography, together with the issue of overdiagnosis and the overall costs of screening, prompted a focus on the development of noninvasive complementary biomarkers to implement lung cancer screening. MicroRNA are a new class of blood-based biomarkers useful for early lung cancer detection and prognosis definition. Here, we discuss the seminal publications that reported circulating microRNA signatures with the greatest potential to impact clinical activity and patient care.

Original languageEnglish
Pages (from-to)801-813
Number of pages13
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Keywords

  • Biomarkers
  • circulating microRNA
  • LDCT
  • lung cancer
  • Screening

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging'. Together they form a unique fingerprint.

  • Cite this